Investigation of the effect of mesalazine on tau protein and its role as an inhibitor of tau fibrillation: an experimental and bioinformatics study

Document Type : Research Paper

Authors
1 Department of Biology, Faculty of Basic Sciences, Lorestan University, Khorramabad, Iran
2 Department of Biology, School of Sciences, Razi University, Kermanshah, Iran
10.22034/cmr.2026.8704.3339
Abstract
Alzheimer's disease is a progressive condition marked by the formation of neurotic plaques by beta-amyloid, neurofibrillary tangles composed of phosphorylated tau, and neuronal loss. In the brain, normal tau plays a critical role in stabilizing microtubules. The use of small organic ligands to prevent protein aggregation is an appealing strategy for treating neurodegenerative diseases. Mesalazine (5-amino-2-hydroxybenzoic acid), as a non-steroidal anti-inflammatory drug, is a potential treatment for Crohn's disease and ulcerative colitis patients. In this study, after the purification of tau protein (1N4R isoform), the effect of mesalazine on amyloid fibril aggregation was investigated using several spectroscopic and electron microscopy techniques, as well as molecular dynamics/computational docking methods. Based on the obtained results, mesalazine inhibited the formation of amyloid fibrils in a concentration-dependent manner with varying ratios of 1:4, 1:2, 3:4, 1:1, and 5:4 μM (mesalazine to tau protein). This inhibitory effect is likely due to the presence of an amino group on the aromatic ring. Furthermore, our molecular docking study confirmed the binding of mesalazine to tau protein through hydrogen bonds and hydrophobic interactions. Considering the observed results in laboratory conditions, compounds with a similar structure and functional groups to mesalazine can be synthesized that have the capability to cross the blood-brain barrier, and thus their effect on reducing tau aggregates formation in in vivo conditions can be studied.
Keywords
Subjects

  • Receive Date 17 October 2025
  • Revise Date 30 August 2026
  • Accept Date 29 September 2026